Balyasny Asset Management
MRNS

Balyasny Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Balyasny Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,006
Closed -$17.6K – 3405
2024
Q3 		$17.6K Buy
+10,006
New +$14K ﹤0.01% 2668
2024
Q2 		– Sell
-849,447
Closed -$7.68M – 3255
2024
Q1 		$7.68M Buy
+849,447
New +$8.26M 0.01% 1049
2023
Q4 		– Sell
-15,873
Closed -$128K – 3003
2023
Q3 		$128K Buy
+15,873
New +$132K ﹤0.01% 2094
2023
Q2 		– Sell
-17,423
Closed -$120K – 2994
2023
Q1 		$120K Buy
+17,423
New +$109K ﹤0.01% 2298
2018
Q4 		– Sell
-52,560
Closed -$2.1M – 1842
2018
Q3 		$2.1M Buy
+52,560
New +$1.5M 0.01% 955
2018
Q1 		– Sell
-250,250
Closed -$8.17M – 2398
2017
Q4 		$8.17M Buy
+250,250
New +$6.74M 0.03% 699

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's MRNS Position: Q4 2024 in Review

Balyasny Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 10,006 shares — an estimated $17.6K sold.

Balyasny Asset Management first reported a position in MRNS in Q4 2017 and held it in 6 quarters. The position peaked at $8.17M in Q4 2017. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Balyasny Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 10,006 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $17.6K.
  • Balyasny Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 6 quarters.
  • Balyasny Asset Management's Marinus Pharmaceuticals, Inc position peaked at $8.17M in Q4 2017.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.